<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247193</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-14-0335</org_study_id>
    <nct_id>NCT02247193</nct_id>
  </id_info>
  <brief_title>Improvement of the Appearance of Cleft Lip Scars Using Botox</brief_title>
  <official_title>Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To determine if the use of botulinum toxin during primary cleft lip repair
      improves the cosmetic appearance of the scar

      Study Design: Double blinded randomized controlled trial

      Methods: Study to be completed at an academic tertiary hospital. Patients must be 6 months of
      age or younger with a unrepaired complete unilateral cleft lip and palate requiring a primary
      cheiloplasty. Botulinum toxin will be injected intraoperatively at 4 standardized sites in
      the cleft lip during surgical repair. Control subjects will receive a placebo injection in
      place of the toxin. Surgeons will be blinded to patients that receive the experimental
      injection. Outcomes will be determined using 3D-videography preoperatively and post
      operatively at scheduled visits with a total of one year follow up. A scar assessment
      questionnaire will be completed by parents at select post operative visits. Videography
      images will also be assessed by a blinded expert panel at the completion of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Vancouver Scar Scale - Expert Panel Analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Videography will be sent to an expert panel of select plastic surgeons that will also use the Modified Vancouver Scar Scale to assess scar outcomes in both the control and experimental groups. This panel will be blinded to which patients received botulinum toxin and which received the control injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Vancouver Scar Scale - Parental Assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Parents at select visits will be asked to use the Modified Vancouver Scar Scale to assess scar outcomes of their child. Again parents will be blinded to whether their child received the experimental injection.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Videography assessment suing the aesthetic grading scale</measure>
    <time_frame>2 years</time_frame>
    <description>Videography at the completion of the study will also be assessed for the following measures which are part of the aesthetic grading scale: Matching accuracy of white roll and vermilion border, scar appearance, Cupid's bow form, length of lip, nostril symmetry, alar dome form, and alar base position. Study personnel will be blinded to which patients received the experimental injection.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cleft Lip</condition>
  <condition>Scarring</condition>
  <condition>Cleft Palate</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of botulinum toxin into cleft lip at time of surgical repair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of normal saline into cleft lip at time of surgical repair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Injection of toxin at the time of surgery at cleft lip repair site</description>
    <arm_group_label>Botulinum Toxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Injection</intervention_name>
    <description>Injection of normal saline into cleft lip at time of surgical repair.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Unilateral cleft lip with or without cleft palate, less than 6 months of age

        Exclusion Criteria:

        Bilateral cleft lip, older than 6 months of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaecel O Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaecel O Shah, MD</last_name>
    <email>jaecel.o.shah@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John F Teichgraeber, MD</last_name>
    <phone>713.500.7285</phone>
    <email>John.F.Teichgraeber@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Underwood, BSN/RN</last_name>
      <phone>713-704-4230</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol. 2009 Nov;13(6):511-5. doi: 10.1016/j.ejpn.2008.10.006. Epub 2008 Nov 25.</citation>
    <PMID>19036619</PMID>
  </results_reference>
  <results_reference>
    <citation>Gal√°rraga IM. Use of botulinum toxin in cheiloplasty: A new method to decrease tension. Can J Plast Surg. 2009 Fall;17(3):e1-2.</citation>
    <PMID>20808741</PMID>
  </results_reference>
  <results_reference>
    <citation>Alvarez CM, De Vera MA, Chhina H, Williams L, Durlacher K, Kaga S. The use of botulinum type A toxin in the treatment of idiopathic clubfoot: 5-year follow-up. J Pediatr Orthop. 2009 Sep;29(6):570-5. doi: 10.1097/BPO.0b013e3181b2b3d4.</citation>
    <PMID>19700985</PMID>
  </results_reference>
  <results_reference>
    <citation>Gassner HG, Sherris DA, Friedman O. Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):140-2. doi: 10.1001/archfacial.2009.3.</citation>
    <PMID>19289689</PMID>
  </results_reference>
  <results_reference>
    <citation>Christiansen G, Mohney BG, Baratz KH, Bradley EA. Botulinum toxin for the treatment of congenital entropion. Am J Ophthalmol. 2004 Jul;138(1):153-5.</citation>
    <PMID>15234303</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002 Feb;18(1):35-9.</citation>
    <PMID>11823931</PMID>
  </results_reference>
  <results_reference>
    <citation>Sykes JM. Management of the cleft lip deformity. Facial Plast Surg Clin North Am. 2001 Feb;9(1):37-50. Review.</citation>
    <PMID>11465005</PMID>
  </results_reference>
  <results_reference>
    <citation>Seibert RW. Bilateral cleft nasal repair. Facial Plast Surg. 2000;16(1):69-78. Review.</citation>
    <PMID>11802349</PMID>
  </results_reference>
  <results_reference>
    <citation>Millard DR Jr. Embryonic rationale for the primary correction of classical congenital clefts of the lip and palate. Ann R Coll Surg Engl. 1994 May;76(3):150-60. Review.</citation>
    <PMID>8017808</PMID>
  </results_reference>
  <results_reference>
    <citation>Witt PD, Hardesty RA. Rotation-advancement repair of the unilateral cleft lip. One center's perspective. Clin Plast Surg. 1993 Oct;20(4):633-45. Review.</citation>
    <PMID>8275629</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee JS, Lee KB, Lee YR, Choi YN, Park CW, Park SD, Jung DH, Lee CS. Botulinum Toxin Treatment on Upper Limb Function in School Age Children With Bilateral Spastic Cerebral Palsy: One Year Follow-up. Ann Rehabil Med. 2013 Jun;37(3):328-35. doi: 10.5535/arm.2013.37.3.328. Epub 2013 Jun 30.</citation>
    <PMID>23869330</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2014</study_first_posted>
  <last_update_submitted>May 19, 2018</last_update_submitted>
  <last_update_submitted_qc>May 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jeffrey D. Johnson</investigator_full_name>
    <investigator_title>Resident, PGY-3</investigator_title>
  </responsible_party>
  <keyword>Botulinum Toxin</keyword>
  <keyword>Botox</keyword>
  <keyword>Craniofacial deformity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cleft Lip</mesh_term>
    <mesh_term>Cleft Palate</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

